Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report

"Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report." Scandinavian Journal of Rheumatology, 49(2), pp. 165–166

Acknowledgement

This study was supported by research expenses provided by Shimane University.

Disclosure statement

MM has received speaking fees from Mitsubishi-Tanabe Pharmaceutical and Janssen Pharmaceutical and manuscript fees from Sanofi.  KM has received speaking fee from Eisai, Chugai Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Bristol-Myers Squibb, Janssen Pharmaceutical, Astellas Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Daiichi-Sankyo, Asahi Kasei Pharmaceutical. and AbbVie Japan. HM received speaking fees from Asahi Kasei Pharmaceutical and Ono Pharmaceutical. MY received grants from Asahi Kasei Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, Teijin Pharmaceutical, Eisai, Nippon Kayaku and Mitsubishi-Tanabe Pharmaceutical, instructor fees from Asahi Kasei Pharmaceutical, Kissei Pharmaceutical, Janssen Pharmaceutical, and speaking fees from Ono Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Astellas Pharmaceutical, UCB Japan, Chugai Pharmaceutical, AbbVie Japan, Daiichi-Sankyo, Ayumi Pharmaceutical, Janssen Pharmaceutical, Takeda Pharmaceutical Sanofi, Teijin Pharma, Eli Lilly Japan and Eisai. WY and MT have no conflicts of interest to declare.